Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Class III Obesity Is Associated with Worse Overall Survival in Previously Untreated Younger Patients with Acute Myeloid Leukemia Enrolled on SWOG 1203

Michelle Y. Zhang, Megan Othus, Kerry K McMillen, Harry P. Erba, Guillermo Garcia-Manero, John Pagel, Mohamed Sorror, Mary-Elizabeth M. Percival

Blood (2023) 142 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2023-189455

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Blood (2023) 142 (Supplement 1): 109.

https://doi.org/10.1182/blood-2023-173855

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in the 7 th Decade of Life and Beyond

Mary-Elizabeth M. Percival, Ted Gooley, Chris Davis, Ryan S. Basom, Stephanie J. Lee, Frederick R. Appelbaum, Mohamed Sorror

Blood (2023) 142 (Supplement 1): 3608.

https://doi.org/10.1182/blood-2023-185037

Published: 2023

Journal Articles

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Blood (2022) 140 (Supplement 1): 4636–4638.

https://doi.org/10.1182/blood-2022-169452

Published: 2022

Journal Articles

Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

Brian D Friend, MD, Larisa Broglie, MD MS, Brent Logan, PhD, Caitrin Fretham, MPH, Gary J. Schiller, MD, Bipin N. Savani, MD, Edward Stadtmauer, Saurabh Chhabra, MD, Marcelo C. Pasquini, MDMS, Monica Thakar, MD, Mohamed Sorror, MD MSc

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-140778

Published: 2020

Journal Articles

Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation

Larisa Broglie, MD MS, Brian D Friend, MD, Brent Logan, PhD, Caitrin Fretham, MPH, Gary J. Schiller, MD, Bipin N. Savani, MD, Edward A. Stadtmauer, MD FACP, Saurabh Chhabra, MD, Marcelo C. Pasquini, MDMS, Monica Thakar, MD, Mohamed Sorror, MD MSc

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140637

Published: 2020

Journal Articles

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Sagar S. Patel, MD, Kwang Woo Ahn, PhD, Manoj Khanal, BS, MS, Caitrin Fretham, MPH, Celalettin Ustun, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Shin Mineishi, MD, Bipin N. Savani, MD, Mohamed Sorror, MD MSc, Edward A. Stadtmauer, MD FACP, Brent Logan, PhD, Marcelo C. Pasquini, MDMS, Saurabh Chhabra, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140503

Published: 2020

Journal Articles

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS

H. Joachim Deeg, Bart L. Scott, Min Fang, Howard M. Shulman, Boglarka Gyurkocza, David Myerson, John M. Pagel, Uwe Platzbecker, Aravind Ramakrishnan, Jerald P. Radich, Brenda M. Sandmaier, Mohamed Sorror, Derek L. Stirewalt, Wendy A. Wilson, Rainer Storb, Frederick R. Appelbaum, Ted Gooley

Blood (2012) 120 (7): 1398–1408.

https://doi.org/10.1182/blood-2012-04-423046

Published: 2012

Includes: Supplemental data

Journal Articles

Comorbidity, Lactate Dehydrogenase (LDH), and Chemosensitivity Are Independent Predictors of Mortality after Autologous Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Lymphoma.

Mohamed Sorror, B. Storer, A. Gopal, L. Holmberg, B.M. Sandmaier, W.I. Bensinger, D.G. Maloney, O.W. Press, R.F. Storb

Blood (2007) 110 (11): 616.

https://doi.org/10.1182/blood.V110.11.616.616

Published: 2007

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Andrew R. Rezvani, MD, L. Norasetthada, MD, T. Gooley, PhD, Mohamed Sorror, MD, Stephen J. Forman, MD, Edward Agura, MD, T. Chauncey, MD, PhD, Richard T. Maziarz, MD, Michael Maris, MD, J. Shizuru, MD, PhD, B. Bruno, MD, James C. Wade, MD, T. Lange, MD, Andrew Yeager, MD, Brenda M. Sandmaier, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD

Blood (2007) 110 (11): 3037.

https://doi.org/10.1182/blood.V110.11.3037.3037

Published: 2007

Journal Articles

Impacts of Comorbidities on Outcomes of Patients (pts) Diagnosed with B-Cell Malignancies and Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative (NM) vs Myeloablative (M) Conditioning.

Mohamed Sorror, MD, MSc, Brenda M. Sandmaier, MD, Barry Storer, PhD, Michael B. Maris, MD, David G. Maloney, MD, PhD, Rainer Storb, MD

Blood (2006) 108 (11): 550.

https://doi.org/10.1182/blood.V108.11.550.550

Published: 2006

Journal Articles

Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens.

Olga Sala-Torra, MD, Paul J. Martin, MD, Barry Storer, PhD, Mohamed Sorror, MD, Rainer F. Storb, MD, Brenda M. Sandmaier, MD, Mary E.D. Flowers, MD

Blood (2006) 108 (11): 755.

https://doi.org/10.1182/blood.V108.11.755.755

Published: 2006

Journal Articles

The Joint Role of Comorbidity and Performance Status (PS) in Predicting Morbidity after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (HCT).

Mohamed Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, David G. Maloney, MD, PhD, Michael Pulsipher, MD, Amelia Langston, MD, Michael B. Maris, MD, Dietger Niederwieser, MD, Rainer Storb, MD

Blood (2006) 108 (11): 596.

https://doi.org/10.1182/blood.V108.11.596.596

Published: 2006

Journal Articles

Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT).

Mohamed Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, Michael Maris, MD, Frederic Baron, MD, PhD, David Maloney, MD, PhD, Bart Scott, MD, H. Joachim Deeg, MD, Rainert Storb, MD

Blood (2005) 106 (11): 705.

https://doi.org/10.1182/blood.V106.11.705.705

Published: 2005

Journal Articles

Lessened severe graft-versus-host after “minitransplantations”

Mohamed Sorror, Michael Maris, Razvan Diaconescu, Rainer Storb

Blood (2005) 105 (6): 2614.

https://doi.org/10.1182/blood-2004-10-4039

Published: 2005

Journal Articles

Marrow Allografts after Nonmyeloablative Conditioning: Effect of Cell Dose on Rejection and Degree of Donor Chimerism.

Razvan Diaconescu, MD, Wendy Leisenring, ScD, Christoph Kahl, MD, Mohamed Sorror, MD, Eustacia Zellmer, Michael Maris, MD, Marie-Terese Little, PhD, Rainer Storb, MD

Blood (2004) 104 (11): 1202.

https://doi.org/10.1182/blood.V104.11.1202.1202

Published: 2004

Journal Articles

Myeloablative Versus Nonmyeloablative Hemopoietic Cell Transplantation (HCT) for Patients with Myelodysplasia (MDS) or AML with Multilineage Dysplasia Following MDS (tAML).

Bart L. Scott, Michael Maris, Brenda Sandmaier, Barry Storer, Thomas Chauncey, David G. Maloney, Mohamed Sorror, Rainer Storb, H. Joachim Deeg

Blood (2004) 104 (11): 2320.

https://doi.org/10.1182/blood.V104.11.2320.2320

Published: 2004

Journal Articles

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

Mohamed Sorror, MD, MSc, Michael Maris, MD, Barry Storer, PhD, Brenda Sandmaier, MD, Monic Stuart, MD, Ute Hegenbart, MD, Edward Agura, MD, Thomas Chauncey, MD, Jose Leis, MD, PhD, Michael Pulsipher, MD, Peter McSweeney, MD, Jerry Radich, MD, James Wade, MD, Benedetto Bruno, MD, Amelia Langston, MD, Dietger Niederwieser, MD, Karl Blume, MD, Rainer Storb, MD, David Maloney, MD, PhD

Blood (2004) 104 (11): 2323.

https://doi.org/10.1182/blood.V104.11.2323.2323

Published: 2004

Journal Articles

Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation.

Frederic Baron, Michael Maris, Barry Storer, Brenda Sandmaier, Jens Panse, Thomas Chauncey, Mohamed Sorror, Marie Terese Little, David Maloney, Rainer Storb, Shelly Heimfeld

Blood (2004) 104 (11): 2753.

https://doi.org/10.1182/blood.V104.11.2753.2753

Published: 2004

NARROW

Class III Obesity Is Associated with Worse Overall Survival in Previously Untreated Younger Patients with Acute Myeloid Leukemia Enrolled on SWOG 1203

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Allogeneic Hematopoietic Cell Transplantation in the 7 th Decade of Life and Beyond

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS

Comorbidity, Lactate Dehydrogenase (LDH), and Chemosensitivity Are Independent Predictors of Mortality after Autologous Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Lymphoma.

Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Impacts of Comorbidities on Outcomes of Patients (pts) Diagnosed with B-Cell Malignancies and Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative (NM) vs Myeloablative (M) Conditioning.

Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens.

The Joint Role of Comorbidity and Performance Status (PS) in Predicting Morbidity after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (HCT).

Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT).

Lessened severe graft-versus-host after “minitransplantations”

Marrow Allografts after Nonmyeloablative Conditioning: Effect of Cell Dose on Rejection and Degree of Donor Chimerism.

Myeloablative Versus Nonmyeloablative Hemopoietic Cell Transplantation (HCT) for Patients with Myelodysplasia (MDS) or AML with Multilineage Dysplasia Following MDS (tAML).

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only